Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced the change of its corporate name to Tanabe Pharma Canada, Inc. (TPC), effective immediately.
In July, MTPA's parent company, Mitsubishi Tanabe Pharma Corporation (MTPC), announced it would undergo a corporate name change to Tanabe Pharma Corporation (TP), effective December 1, 2025, following acquisition by Bain Capital, a leading global private investment firm. The new company name, "Tanabe Pharma," reflects the steadfast commitment to further global growth as an R&D-driven pharmaceutical innovator and honoring the legacy of the former Tanabe Seiyaku, one of the world's oldest pharmaceutical companies.
Though taking on a new name, TPC's core values hold strong as the company remains dedicated to advancing science and creating hope for all underserved patient populations with complex needs.
"While our name is changing, our commitment to addressing the unmet needs of patients with serious, difficult-to-treat conditions remains unwavering," said Andy Zylak, President, Tanabe Pharma Canada. "As Tanabe Pharma Canada, we will continue to build on our legacy of serving the ALS community and driving meaningful progress for Canadians living with debilitating diseases."
TPC will continue to pursue a robust pipeline of products for hard-to-treat diseases, including neurodegenerative diseases, inflammatory, and metabolic conditions.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!